Reductions in Childhood Pneumonia Mortality After Vaccination in the United States

dc.contributor.authorPaternina-Caicedo, Angel
dc.contributor.authorSmith, Adrian D.
dc.contributor.authorBuchanich, Jeanine
dc.contributor.authorGarcia-Calavaro, Christian
dc.contributor.authorAlvis-Guzman, Nelson
dc.contributor.authorNarvaez, Javier
dc.contributor.authorde Oliveira, Lucia Helena
dc.contributor.authorDe la Hoz-Restrepo, Fernando
dc.contributor.orcidPaternina-Caicedo, Angel [0000-0002-6332-5174]
dc.date.accessioned2023-08-03T17:11:26Z
dc.date.available2023-08-03T17:11:26Z
dc.date.issued2023
dc.description.abstractenglishBACKGROUND: We aim to estimate the magnitude of the reduction in pneumococcal pneumonia and meningitis mortality after the mass introduction of pneumococcal conjugate vaccine (PCV)7 and PCV13 in children in the United States. METHODS: We assessed the trends in mortality rates from pneumococcal pneumonia and meningitis, in the United States between 1994 and 2017. We fitted an interrupted time-series negative binomial regression model (adjusted by trend, seasonality, PCV7/PCV13 coverage, and H. influenzae type b vaccine coverage) to estimate the counterfactual rates without vaccination. We reported a percent reduction in mortality estimates relative to the projected no-vaccination scenario, using the formula 1 minus the incidence risk ratio, with 95% confidence intervals (CIs). RESULTS: Between 1994 and 1999 (the prevaccination period), the all-cause pneumonia mortality rate for 0-1-month-old children was 2.55 per 100,00 pop., whereas for 2-11 months-old children, this rate was 0.82 deaths per 100,000 pop. During the PCV7-period in 0-59-month-old children in the United States, the adjusted reduction of all-cause pneumonia was 13% (95% CI: 4-21) and 19% (95% CI: 0-33) of all-cause meningitis For PCV13, the reductions in this age group were 21% (95% CI: 4-35) for all-cause pneumonia mortality and 22% (95% CI: -19 to 48) for all-cause meningitis mortality. PCV13 had greater reductions of all-cause pneumonia than PCV13 in 6-11-month-old infants. CONCLUSIONS: The universal introduction of PCV7, and later PCV13, for children 0-59 months old in the United States was associated with decreases in mortality due to all-cause pneumonia.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1097/INF.0000000000003971
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn0891-3668
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/11250
dc.language.isoeng
dc.publisherWolters Kluwer Healthspa
dc.publisher.journalThe Pediatric infectious disease journalspa
dc.relation.ispartofseriesThe Pediatric infectious disease journal, 0891-3668, 42 (8), 2023, 723 - 729spa
dc.relation.urihttps://journals.lww.com/pidj/Fulltext/2023/08000/Reductions_in_Childhood_Pneumonia_Mortality_After.27.aspx
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_14cb
dc.rights.localAcceso cerradospa
dc.subjectVacunaciónspa
dc.subjectEficaciaspa
dc.subjectVacuna antineumocócicaspa
dc.subjectEstados Unidosspa
dc.subject.keywordsImmunizationspa
dc.subject.keywordsEffectivenessspa
dc.subject.keywordsPneumococcal vaccinespa
dc.subject.keywordsUnited Statesspa
dc.titleReductions in Childhood Pneumonia Mortality After Vaccination in the United Statesspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.coarversionhttps://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Reductions_in_Childhood_Pneumonia_Mortality_After.27.pdf
Tamaño:
1.15 MB
Formato:
Adobe Portable Document Format
Descripción:
Reductions in Childhood Pneumonia Mortality After Vaccination in the United States

Colecciones